In the acute phase, a trial of 8-20 ECT treatments, in addition to continuing antipsychotics, may be indicated for catatonic schizophrenia, treatment-resistant schizophrenia, or severe depression ...

Insurer access challenges likely lie ahead for the novel schizophrenia drug Cobenfy, given its considerably higher price than ...

One important challenge of schizophrenia treatment is to remember to take medicine every day. With Uzedy given once a month or every two months, people with schizophrenia may stay stable for ...

A 2012 study found 50% of people with schizophrenia don’t take their prescribed medication, and it’s not just because of side effects. A 2020 research review found we disengage with treatment ...

Lumateperone, an atypical antipsychotic, is currently approved under the brand name Caplyta for the treatment of schizophrenia in adults.

Intra-Cellular Therapies’ atypical antipsychotic medication Caplyta has been on a roll, delivering fast commercial growth and coming up triumphant in yet another late-stage trial. | Intra-Cellular ...

Intra-Cellular Therapies' lumateperone shows significant efficacy in reducing schizophrenia relapse rates, with a 63% risk ...

Schizophrenia may be misdiagnosed as depression or bipolar disorder, which delays treatment and negatively impacts the prognosis, explained Megan Ehret, PharmD, MS, BCPP, of the University of ...

The study also included an 18-week open-label phase, during which patients with Schizophrenia were treated with Lumateperone 42 mg per day. The biopharmaceutical company found that the time to relapse ...

is catatonia: characterised by a host of abnormal motor behaviours occurring alongside stupor or excitement. It is no longer ...

Treatment for bipolar I disorder or schizophrenia typically consists of prescription medication as well as some form of psychological therapy. Despite this, less than 10 percent of patients who ...

Some people who took a new schizophrenia drug for one year improved with only ... noting that fewer or milder side effects could mean people will stay in treatment longer. That could mean fewer ...